Novartis quietly buries another failed eczema drug, with a $485M hit embedded in the footnotes
Back in late 2016, when Vas Narasimhan was the chief medical officer at giant Novartis, he arranged a buyout of Ziarco primarily so he …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
